(-)-Cryptopleurine
(Synonyms: (R)-Cryptopleurine, NSC 19912) 目录号 : GC48635
An alkaloid with diverse biological activities
Cas No.:482-22-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
(-)-Cryptopleurine is an alkaloid that has been found in Lauraceae and has diverse biological activities.1 It inhibits the growth of human A375 melanoma, A431 epidermoid carcinoma, A549 lung, MES-SA uterine sarcoma, and MCF-7 breast cancer cells (IC50 = 3 nM for all).2 (-)-Cryptopleurine inhibits hypoxia-induced gene expression in a hypoxia response element (HRE) reporter assay (IC50 = 8.7 nM).3 (-)-Cryptopleurine (500 µg/ml) prevents lesion formation in tobacco (N. tabacum) plants infected with tobacco mosaic virus (TMV).1 It also inhibits protein synthesis by yeast and mammalian ribosomes.4,5
1.Wang, Z., Feng, A., Cui, M., et al.First discovery and stucture-activity relationship study of phenanthroquinolizidines as novel antiviral agents against Tobacco Mosaic Virus (TMV)PLoS One7(12)e52933(2012) 2.Banwell, M.G., Bezos, A., Burns, C., et al.C8c-C15 monoseco-analogues of the phenanthroquinolizidine alkaloids julandine and cryptopleurine exhibiting potent anti-angiogenic propertiesBioorg. Med. Chem. Lett.16(1)181-185(2006) 3.Cai, X.F., Jin, X., Lee, D., et al.Phenanthroquinolizidine alkaloids from the roots of Boehmeria pannosa potently inhibit hypoxia-inducible factor-1 in AGS human gastric cancer cellsJ. Nat. Prod.69(7)1095-1097(2006) 4.Battaner, E., and Vazquez, D.Inhibitors of protein synthesis by ribosomes of the 80-S typeBiochim. Biophys. Acta254(2)316-330(1971) 5.Pestka, S., Rosenfeld, H., Harris, R., et al.Studies on transfer ribonucleic acid-ribosome complexes. XXI. Effect of antibiotics on peptidyl-puromycin synthesis by mammalian polyribosomesJ. Biol. Chem.247(21)6895-6900(1972)
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.649 mL | 13.245 mL | 26.4901 mL |
| 5 mM | 0.5298 mL | 2.649 mL | 5.298 mL |
| 10 mM | 0.2649 mL | 1.3245 mL | 2.649 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。